Administration of nimotuzumab combined with cisplatin plus 5-fluorouracil as induction therapy improves treatment response and tolerance in patients with locally advanced nasopharyngeal carcinoma receiving concurrent radiochemotherapy: a multicenter randomized controlled study
Abstract Background Nimotuzumab (NTZ) is an anti-EGFR monoclonal antibody. However,the effect of targeted drugs combined with induction therapy in locally advanced nasopharyngeal carcinoma remains unclear. The aim of this study is to investigate the safety and efficacy of NTZ combined with cisplatin...
Main Authors: | Ying Lu, Dagui Chen, Jinhui Liang, Jianquan Gao, Zhanxiong Luo, Rensheng Wang, Wenqi Liu, Changjie Huang, Xuejian Ning, Meilian Liu, Haixin Huang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-12-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12885-019-6459-6 |
Similar Items
-
Multi-center Clinical Study of Nimotuzumab Combined with PF Regimen in Induction Treatment of Locally Advanced Nasopharyngeal Carcinoma
by: LU Ying, et al.
Published: (2019-04-01) -
Induction chemotherapy plus nimotuzumab followed
by concurrent chemoradiotherapy for advanced
nasopharyngeal carcinoma
by: Xinmao Song, et al.
Published: (2019-07-01) -
Radiosensitivity enhancement by combined treatment of nimotuzumab and celecoxib on nasopharyngeal carcinoma cells
by: Huang JF, et al.
Published: (2018-07-01) -
Comparison of radiotherapy combined with nimotuzumab vs. chemoradiotherapy for locally recurrent nasopharyngeal carcinoma
by: Jing-Feng Zong, et al.
Published: (2021-11-01) -
Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy with or without nimotuzumab in the treatment of locally advanced nasopharyngeal carcinoma: a retrospective study
by: Zhi Yang, et al.
Published: (2023-11-01)